<DOC>
	<DOCNO>NCT00560937</DOCNO>
	<brief_summary>This pilot study pregnenolone augmentation treatment schizophrenia . The goal placebo-controlled study provide preliminary efficacy data potential pregnenolone effect cognitive symptom negative symptom patient schizophrenia . Depressive symptom positive symptom also assess .</brief_summary>
	<brief_title>Pilot Study Pregnenolone Augmentation Targeting Cognitive Symptoms Persistently Symptomatic Patients With Schizophrenia</brief_title>
	<detailed_description>See brief summary</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Neurobehavioral Manifestations</mesh_term>
	<criteria>1 . 1865 year age , ethnic group , either sex 2 . Diagnostic Statistical Manual , 4th edition ( DSM IV ) diagnosis schizophrenia schizoaffective disorder 3 . Ability participate fully informed consent process , legal guardian able participate inform consent process . 4 . Patient cohort enrich moderate severe cognitive symptom ( composite Brief Assessment Cognition Schizophrenia ( BACS ) score 03 SD mean ) . 5 . No change antipsychotic 8 week longer . No change antipsychotic dose 4 week longer . 6 . No change anticholinergic , benzodiazepine , mood stabilizer medication 4 week longer . 7 . No anticipated need alter medication ( antipsychotic , anticholinergic , benzodiazepine , mood stabilizer ) 10week duration study . 1 . Unstable medical illness neurologic illness ( seizure , cerebrovascular accident ) ; history prostate , breast , uterine , ovarian cancer . 2 . Use oral contraceptive hormonal supplementation estrogen . 3 . Other concomitant medication medical condition address casebycase base determine exclusionary . 4 . Active expression suicidal homicidal ideation . 5 . Comorbid substance dependence ( nicotine dependence ) , present symptom likely substanceinduced , judge study physician . 6 . Female patient pregnant breastfeeding . 7 . Known allergy study medication . 8 . Drugs narrow therapeutic index ( e.g . thioridazine , mesoridazine , ziprasidone , clozapine , etc ) exclude suggested Federal Drug Administration ( FDA ) ; patient take agent eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Pregnenolone</keyword>
	<keyword>Cognition</keyword>
	<keyword>Negative Symptoms</keyword>
</DOC>